Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children

H. Tesfaye, R. Branova, E. Klapkova, R. Prusa, D. Janeckova, P. Riha, P. Sedlacek, P. Keslova, J. Malis,

. 2014 ; 19 (-) : 214-24.

Jazyk angličtina Země Polsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc14074216

BACKGROUND: Series of observations indicate PK/PD variability challenging the accuracy of the body-weight based busulfan (Bu) dosing schedule for (HSCT) conditioning therapy. The purpose of this communication is to describe the frequency of dose changes in initially body-weight-based fixed IV Bu dose and to emphasize the importance of TDM. MATERIAL AND METHODS: Sixty-two children (ages 2 months-18 years) were treated with IV busulfan doses based on body weight for myeloablation. TDM utilizing a limited sample strategy (trough concentration immediately before the 5th dose, followed by samples immediately after the end of the 2-h infusion peak, 4 h, and 6 h from initiation of the infusion) was performed in 46 of 62 subjects. Busulfan concentrations were determined by high-performance liquid chromatography (HPLC). AUC was calculated according to the trapezoidal rule. RESULTS: We observed trough levels of 25-1244 µg/L, peak levels of 849-4586 µg/L, and AUC of 2225-12818 µg/L·h following body weight-based high-dose busulfan. The doses were changed in 54% of cases. AUC in 5 of 9 patients with VOD were within target, in 3 patients AUS was higher, and in 1 patient AUC was lower. One of the 2 patients with neurotoxicity had higher AUC. Engraftment was 100%, but relapse occurred in 25% of cases. CONCLUSIONS: Our results demonstrate that even with IV busulfan, intra-individual PK/PD variability is challenging. Although AUC does not necessarily correspond with outcomes (due to the role of other factors the fact that doses were changed in 54% of cases underlines the importance of TDM.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14074216
003      
CZ-PrNML
005      
20141007102332.0
007      
ta
008      
141006s2014 pl f 000 0|eng||
009      
AR
024    7_
$a 10.12659/AOT.889933 $2 doi
035    __
$a (PubMed)24811685
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a pl
100    1_
$a Tesfaye, Hundie $u Department of Medical Chemistry and Clinical Biochemistry, Division of Clinical Pharmacology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
245    14
$a The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children / $c H. Tesfaye, R. Branova, E. Klapkova, R. Prusa, D. Janeckova, P. Riha, P. Sedlacek, P. Keslova, J. Malis,
520    9_
$a BACKGROUND: Series of observations indicate PK/PD variability challenging the accuracy of the body-weight based busulfan (Bu) dosing schedule for (HSCT) conditioning therapy. The purpose of this communication is to describe the frequency of dose changes in initially body-weight-based fixed IV Bu dose and to emphasize the importance of TDM. MATERIAL AND METHODS: Sixty-two children (ages 2 months-18 years) were treated with IV busulfan doses based on body weight for myeloablation. TDM utilizing a limited sample strategy (trough concentration immediately before the 5th dose, followed by samples immediately after the end of the 2-h infusion peak, 4 h, and 6 h from initiation of the infusion) was performed in 46 of 62 subjects. Busulfan concentrations were determined by high-performance liquid chromatography (HPLC). AUC was calculated according to the trapezoidal rule. RESULTS: We observed trough levels of 25-1244 µg/L, peak levels of 849-4586 µg/L, and AUC of 2225-12818 µg/L·h following body weight-based high-dose busulfan. The doses were changed in 54% of cases. AUC in 5 of 9 patients with VOD were within target, in 3 patients AUS was higher, and in 1 patient AUC was lower. One of the 2 patients with neurotoxicity had higher AUC. Engraftment was 100%, but relapse occurred in 25% of cases. CONCLUSIONS: Our results demonstrate that even with IV busulfan, intra-individual PK/PD variability is challenging. Although AUC does not necessarily correspond with outcomes (due to the role of other factors the fact that doses were changed in 54% of cases underlines the importance of TDM.
650    _2
$a adjuvancia imunologická $x aplikace a dávkování $7 D000276
650    _2
$a mladiství $7 D000293
650    _2
$a tělesná hmotnost $7 D001835
650    _2
$a busulfan $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D002066
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a vysokoúčinná kapalinová chromatografie $7 D002851
650    _2
$a dithiokarb $x aplikace a dávkování $7 D004050
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a monitorování léčiv $x metody $7 D016903
650    _2
$a transplantace hematopoetických kmenových buněk $x metody $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a intravenózní infuze $7 D007262
650    _2
$a myeloablativní agonisté $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D019653
650    _2
$a příprava pacienta k transplantaci $x škodlivé účinky $x metody $7 D019172
655    _2
$a časopisecké články $7 D016428
700    1_
$a Branova, Romana $u Department of Medical Chemistry and Clinical Biochemistry, Division of Clinical Pharmacology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Klapkova, Eva $u Department of Medical Chemistry and Clinical Biochemistry, Division of Clinical Pharmacology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Prusa, Richard $u Department of Medical Chemistry and Clinical Biochemistry, Division of Clinical Pharmacology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Janeckova, Daniela $u Department of Paediatric Hematology and Oncology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Riha, Petr $u Department of Paediatric Haematology and Oncology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic., Prague, Czech Republic.
700    1_
$a Sedlacek, Petr $u Department of Paediatric Haematology and Oncology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic., Prague, Czech Republic.
700    1_
$a Keslova, Petra $u Department of Paediatric Haematology and Oncology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic., Prague, Czech Republic.
700    1_
$a Malis, Josef $u Department of Paediatric Haematology and Oncology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic., Prague, Czech Republic.
773    0_
$w MED00000447 $t Annals of transplantation : quarterly of the Polish Transplantation Society $x 2329-0358 $g Roč. 19, č. - (2014), s. 214-24
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24811685 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20141006 $b ABA008
991    __
$a 20141007102809 $b ABA008
999    __
$a ok $b bmc $g 1042099 $s 873128
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 19 $c - $d 214-24 $i 2329-0358 $m Annals of Transplantation $n Ann Transplant $x MED00000447
LZP    __
$a Pubmed-20141006

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...